These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1091122)

  • 1. Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
    McLellan DL; Chalmers RJ; Johnson RH
    Acta Neurol Scand; 1975 Jan; 51(1):74-82. PubMed ID: 1091122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
    Rinne UK; Sonninen V; Marttila R
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson disease treated with a suspected dopamine receptor agonist.
    Chase TN; Woods AC; Glaubiger GA
    Arch Neurol; 1974 May; 30(5):383-6. PubMed ID: 4821783
    [No Abstract]   [Full Text] [Related]  

  • 4. Proceedings: Effects of piribedil (ET 495)--a dopaminergic receptor stimulating agent in Parkinson's disease.
    Lieberman A; Le Brun Y; Zolfaghari M
    Psychopharmacol Bull; 1974 Jul; 10(3):42-3. PubMed ID: 4419369
    [No Abstract]   [Full Text] [Related]  

  • 5. [Piribedil in the treatment of Parkinson disease (author's transl)].
    Nardini M; Sciannandrone R; Fieschi C; De Simone G
    Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain dopamine turnover and the relief of parkinsonism.
    Rinne UK; Sonninen V; Marttila R
    Adv Exp Med Biol; 1977; 90():267-75. PubMed ID: 930747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of dopaminergic receptor stimulating agent (Pribedil, ET 495) in Parkinson's disease.
    Lieberman A; Le Brun Y; Boal D; Zolfaghari M
    Adv Biochem Psychopharmacol; 1974; 12(0):415-25. PubMed ID: 4425258
    [No Abstract]   [Full Text] [Related]  

  • 8. Piribedil, a dopamine agonist, in Parkinson's disease.
    Sweet RD; Wasterlain CG; McDowell FH
    Clin Pharmacol Ther; 1974 Dec; 16(6):1077-82. PubMed ID: 4611465
    [No Abstract]   [Full Text] [Related]  

  • 9. Amphetamines in the treatment of Parkinson's disease.
    Parkes JD; Tarsy D; Marsden CD; Bovill KT; Phipps JA; Rose P; Asselman P
    J Neurol Neurosurg Psychiatry; 1975 Mar; 38(3):232-7. PubMed ID: 1097600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain dopamine turnover and the relief of parkinsonism.
    Rinne UK; Marttila R; Sonninen V
    Arch Neurol; 1977 Oct; 34(10):626-9. PubMed ID: 907536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic mechanisms in patients with extrapyramidal disease.
    Chase TN; Shoulson I
    Adv Neurol; 1975; 9():359-66. PubMed ID: 1146660
    [No Abstract]   [Full Text] [Related]  

  • 12. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
    Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
    Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
    Rondot P; Bathien N; Dumas JL
    Adv Neurol; 1975; 9():373-81. PubMed ID: 1096574
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical studies of dopaminergic mechanisms.
    Chase TN
    Adv Biochem Psychopharmacol; 1974; 12(0):427-34. PubMed ID: 4421041
    [No Abstract]   [Full Text] [Related]  

  • 15. Piribedil in Parkinson's syndrome: a clinical study.
    Engel J; Granerus AK; Svanborg A
    Eur J Clin Pharmacol; 1975 Apr; 8(3-4):223-6. PubMed ID: 183960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on piribedil in Parkinsonism.
    Lieberman AN; Shopsin B; Brun YL; Boal D; Zolfaghari M
    Adv Neurol; 1975; 9():399-407. PubMed ID: 125032
    [No Abstract]   [Full Text] [Related]  

  • 17. Proceedings: Clinical studies of dopaminergic mechanisms.
    Chase TN
    Psychopharmacol Bull; 1974 Jul; 10(3):43-4. PubMed ID: 4419336
    [No Abstract]   [Full Text] [Related]  

  • 18. Amantadine hydrochloride in treatment of Parkinsonism.
    Nagaswami S; Nagaswami R
    Dis Nerv Syst; 1973; 34(5):253-8. PubMed ID: 4782280
    [No Abstract]   [Full Text] [Related]  

  • 19. Piribedil: its synergistic effect in multidrug regimens for parkinsonism.
    Feigenson JS; Sweet RD; McDowell FH
    Neurology; 1976 May; 26(5):430-3. PubMed ID: 944394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piribedil (ET 495) in the treatment of Parkinson's disease combined with amantadine or levodopa.
    Callaghan N; Fitzpatrick E; O'Mahony JB
    Acta Neurol Scand; 1975 Sep; 52(3):179-86. PubMed ID: 1098359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.